- Report
- January 2024
- 285 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- August 2022
- 117 Pages
Global
From €4284EUR$4,500USD£3,662GBP
- Report
- March 2021
- 75 Pages
Global
€20946EUR$22,000USD£17,904GBP
- Report
- June 2018
- 15 Pages
Global
From €9521EUR$10,000USD£8,138GBP
Inbrija is a type of Central Nervous System (CNS) drug used to treat Parkinson's disease. It is an inhaled form of levodopa, a medication used to treat the symptoms of Parkinson's. Inbrija is designed to provide fast-acting relief from "off" episodes, which are periods of time when Parkinson's symptoms become more severe. It is taken as needed, up to four times a day, and is intended to be used in combination with other Parkinson's medications.
Inbrija is part of a larger market of CNS drugs, which includes medications used to treat a variety of neurological conditions, such as Alzheimer's disease, epilepsy, and multiple sclerosis. These drugs are used to manage symptoms, slow the progression of the disease, and improve quality of life.
Some companies in the CNS drug market include AbbVie, Biogen, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more